AWA
XERS icon

Arkadios Wealth Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Arkadios Wealth Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,000
Closed -$17K – 593
2022
Q3 		$17K Buy
+11,000
New +$18.2K ﹤0.01% 521

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Arkadios Wealth Advisors's XERS Position: Q4 2022 in Review

Arkadios Wealth Advisors sold out of Xeris Biopharma Holdings (XERS) in Q4 2022, closing a stake of 11,000 shares — an estimated $17K sold.

Arkadios Wealth Advisors first reported a position in XERS in Q3 2022 and held it in 1 quarter. The position peaked at $17K in Q3 2022. 97 funds tracked by Wall St. Rank hold XERS as of Q4 2022.

  • Arkadios Wealth Advisors reported no remaining Xeris Biopharma Holdings position as of Q4 2022 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 11,000 Xeris Biopharma Holdings shares in Q4 2022, an estimated $17K.
  • Arkadios Wealth Advisors first reported a position in Xeris Biopharma Holdings in Q3 2022 and held it in 1 quarter.
  • Arkadios Wealth Advisors's Xeris Biopharma Holdings position peaked at $17K in Q3 2022.
  • 97 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2022.

Based on Arkadios Wealth Advisors's 13F filing for Q4 2022, filed 11 Jan 2023.